Oculis (NASDAQ:OCS – Get Free Report) was upgraded by research analysts at Guggenheim to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.
Several other analysts have also recently issued reports on OCS. Stifel Nicolaus upped their price objective on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Tuesday, April 21st. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. JPMorgan Chase & Co. increased their price target on Oculis from $38.00 to $42.00 and gave the company an “overweight” rating in a report on Monday. Finally, HC Wainwright lifted their price objective on Oculis from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Oculis currently has an average rating of “Moderate Buy” and a consensus price target of $49.38.
Read Our Latest Stock Report on OCS
Oculis Price Performance
Oculis (NASDAQ:OCS – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The firm had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.25 million. On average, analysts expect that Oculis will post -2.21 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Oculis
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its position in Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after purchasing an additional 878 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Oculis by 100.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC purchased a new stake in Oculis in the 4th quarter valued at about $80,000. Geode Capital Management LLC raised its holdings in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after buying an additional 6,384 shares during the period. Finally, Koshinski Asset Management Inc. acquired a new position in Oculis in the first quarter valued at about $238,000. Institutional investors and hedge funds own 22.30% of the company’s stock.
About Oculis
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.
See Also
- Five stocks we like better than Oculis
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
